LEYRE MARTIN RODRIGUEZ

Dr. LEYRE MARTIN RODRIGUEZ

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2018 in The Journal of Rheumatology
Verified
Journal Article
Open access
PDF file
MPMaria Prendecki
Maria Prendecki
LRLEYRE MARTIN RODRIGUEZ
LEYRE MARTIN RODRIGUEZ
ATAnisha Tanna
Anisha Tanna
MAMarilina Antonelou
Marilina Antonelou
CPCharles D. Pusey
Charles D. Pusey
Objective.: Antineutrophil cytoplasmic antibodies (ANCA)–associated vasculitis (AAV) has been linked with thyroid disease as a result of antithyroid medications. We assessed the prevalence of thyroid disease in our patients with AAV.Methods.: Clinical records of 279 patients with AAV diagnosed between 1991 and 2014 were analyzed.Results.: Thyroid disease was identified in 21.5% of patients, but only 2 had previously received propylthiouracil. There was a greater proportion of female patients, patients with antimyeloperoxidase antibodies, and patients with renal disease in the group with thyroid disease.Conclusion.: Our data show a higher prevalence of thyroid disease in patients with AAV than the general population. This was not attributable to antithyroid drugs.

22 November 2019 in Clinical Kidney Journal
Verified
Journal Article
Open access
PDF file
JPJosé Portoles
José Portoles
BDBeatriz Durá-Gúrpide
Beatriz Durá-Gúrpide
JMJosé Luis Merino-Rivas
José Luis Merino-Rivas
LRLEYRE MARTIN RODRIGUEZ
LEYRE MARTIN RODRIGUEZ
CHCovadonga Hevia-Ojanguren
Covadonga Hevia-Ojanguren
TGthe GCDP Study Group
the GCDP Study Group
The efficacy of intravenous (IV) ferric carboxymaltose (FCM) has been demonstrated in haemodialysis and non-dialysis studies, but evidence is lacking in patients undergoing peritoneal dialysis (PD). This multicentre, retrospective study evaluated the effectiveness and safety of FCM in patients on PD over 12 months. We retrospectively reviewed the electronic medical records of PD patients who initiated FCM treatment between 2014 and 2017 across seven Spanish centres. Ninety-one patients were included in the safety population (mean ± SD age 57.7 ± 15.0 years) and 70 in the efficacy population (mean age 50.9 ± 14.5 years). No hypersensitivity reaction, FCM discontinuation or dose adjustment due to a serious adverse event (SAE) was registered in the safety population. The most common non-SAEs reported were headache (four events), mild hypotension (three events) and hypertension (two events), among others. In the efficacy population (n = 70), 68.6% of patients achieved ferritin levels of 200–800 ng/mL, 78.4% achieved transferrin saturation (TSAT) >20%, and 62.8% achieved TSAT >20% and ferritin >200 ng/mL after 12 months of FCM initiation (P < 0.01). Haemoglobin (Hb) levels were maintained at >11 g/dL with a lower dose of darbepoetin throughout the follow-up. The sub-analysis of patients naïve to IV iron and with absolute or relative iron deficiency (n = 51) showed that 76.5% reached ferritin >200 ng/mL, 80.4% TSAT >20% and Hb increased (1.2 g/dL) after 4 months of FCM treatment (P < 0.01). In this multicentre, retrospective, real-world study conducted in the PD population, FCM was effective, safe and easy to administer during routine clinical visits.

28 October 2022 in Clinical Kidney Journal
Verified
Journal Article
Open access
PDF file
JPJosé Portoles
José Portoles
PLPaula Lopez-Sanchez
Paula Lopez-Sanchez
LRLEYRE MARTIN RODRIGUEZ
LEYRE MARTIN RODRIGUEZ
MSMaría Luisa Serrano-Salazar
María Luisa Serrano-Salazar
MVMaria Valdenebro-Recio
Maria Valdenebro-Recio
AOAlberto Ortiz
Alberto Ortiz
Chronic kidney disease (CKD) is a risk factor for death from COVID-19, and COVID-19 may cause acute kidney injury (AKI) that also influences outcomes. There is little information on the independent contribution of CKD and AKI to the risk of death in COVID-19 on different waves, as CKD is a key risk factor for AKI. We have studied the epidemiology of CKD and AKI in 2,878 patients hospitalized for COVID-19 and their independent association with in-hospital mortality in the two largest pre-vaccination COVID-19 waves in Madrid, Spain. Hospitalized COVID-19 patients were grouped into four mutually exclusive categories: previous-CKD, community-acquired AKI (CA-AKI), hospital-acquired AKI (HA-AKI) and normal renal function throughout hospitalization. Pre-existent or acquired kidney involvement was observed in 35.5% and 36.8% of COVID-19 patients in the 1st and 3rd waves, respectively. Overall, 13.9% of patients with normal kidney function on arrival, developed HA-AKI. In the 3rd wave, CA-AKI was more common than in the 1st wave. Overall, 9% to 20% of CKD cases and 22% to 40% of AKI cases remained undiagnosed in the discharge report. CKD, CA-AKI and HA-AKI were independently associated with risk of death in multivariate analysis, HA-AKI, which was usually mild, being the most relevant independent risk factor for in-hospital mortality. A model including kidney involvement category, age, Charlson index, admission LDH and lymphocytes predicted death with a ROC/AUC of 0.898. In conclusion, CKD and AKI were common in pre-vaccination waves among hospitalized COVID-19 patients and were independent risk factors for death, even when AKI was mild to moderate, and despite improvements in treatment.

1 November 2019 in Nefrología
Verified
Journal Article
Open access
PLPaula Lopez-Sanchez
Paula Lopez-Sanchez
JPJosé Portoles
José Portoles
LRLEYRE MARTIN RODRIGUEZ
LEYRE MARTIN RODRIGUEZ
FTFernando Tornero
Fernando Tornero
AMArturo José Ramos Martín-Vegue
Arturo José Ramos Martín-Vegue
JBJuan Luis Cruz Bermúdez
Juan Luis Cruz Bermúdez
Chronic kidney disease has a high prevalence and economic impact, and an increased risk of hospitalization. Although there are public regional and country registries, we have not found references to estimate the impact of renal replacement therapy (RRT) on hospital admissions. We obtained authorization from the ethics committee and health authorities to integrate the REMER [Madrid Kidney Disease Registry] (2013-2014) and Minimum Basic Data Set (2013-2015) databases and to analyze the admissions during the first year of RRT. 767 patients started RRT in all the hospitals of our region across all RRT modalities. More than a third of the patients start dialysis during a hospital admission. This unplanned start, more common in HD than PD, shows relevant differences in patient profile or admission characteristics. Without considering this initial episode, almost 60% of patients were admitted during their first year. The hospitalization rate was 1.2admissions/patient, higher in HD than in TX or PD; the mean length of stay was 8.6days. The estimated cost of admissions during the first year is €12,006/patient. Our analysis ensures the exhaustive inclusion of all episodes and accurate estimation based on the discharge form. The impact of RRT on hospitals has been underestimated and is very relevant when calculating the total cost of RRT. Results from other countries cannot be extrapolated due to differences in the health system and patient profile. The integration of clinical databases could open up an opportunity that needs only institutional support for its development.

25 January 2016 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
MGM. Garbiras
M. Garbiras
ASAmir Shabaka
Amir Shabaka
NCN. Calvo
N. Calvo
LRLEYRE MARTIN RODRIGUEZ
LEYRE MARTIN RODRIGUEZ
MHMaria Ángeles Moreno de la Higuera
Maria Ángeles Moreno de la Higuera
AFAna Isabel Sánchez Fructuoso
Ana Isabel Sánchez Fructuoso

1 August 2025 in Journal Of Nephrology
Verified
Journal Article
Open access
PDF file
AMAna Muñoz-Sánchez
Ana Muñoz-Sánchez
LRLEYRE MARTIN RODRIGUEZ
LEYRE MARTIN RODRIGUEZ
PLPaula Lopez-Sanchez
Paula Lopez-Sanchez
MRMaria Valdenebro Recio
Maria Valdenebro Recio
MSMaria Luisa Serrano-Salazar
Maria Luisa Serrano-Salazar
JPJosé Portoles
José Portoles
Background: Acute Kidney Injury (AKI) is frequent and is associated with adverse outcomes. Aims: To analyze the impact of community-acquired and hospital-acquired AKI on in-hospital and five-year post-discharge kidney replacement therapy (KRT) requirement in the pre-COVID era. Methods: We linked the regional health system database of 419,851 admissions to the regional KRT registry. We grouped all admissions into 3 categories: community-acquired AKI, where AKI was the primary diagnosis, and hospital-acquired AKI, where AKI was an additional diagnosis alongside another primary condition. Admissions without this code were grouped into a third category (no AKI). We excluded patients aged under 18 years old, those with previous KRT, and pregnant women. The study was approved by the ethics committee. Patients were followed up for five years after discharge. Results: Community-acquired AKI accounted for 0.6% of all admissions, associated prolonged average hospital stays, and increased mortality rates. In-hospital KRT administration was required in 3.1% of cases, and after a mean follow-up time of 459 days, 7.2% of these patients began chronic KRT. Hospital-acquired AKI represented 6.1% of all admissions and was associated with the highest mortality rate (22.9% vs 14.4% in the community-acquired AKI group) and the longest average hospital stay (12.6 days vs 7.1 in the no AKI group). Only 0.5% of hospital-acquired AKI cases required KRT during the AKI episode, while 2% of these patients initiated chronic KRT after a mean follow-up time of 594 days. Conclusions: AKI continues to be a frequent problem in clinical practice, negatively influencing patient morbidity and mortality, and increasing the risk of starting KRT in the medium-long term. Graphical